The MCL (Mantle cell lymphoma) and CLL (chronic lymphocytic leukemia) have both been treated with the BTK inhibitors, by inhibiting BCR signaling and controlling innate or adaptive immunity (Burger and Wiestner 2018). Here, BTK is linked to B-cell chronic lymphocytic leukemia.